2022-05-052022-05-052004-06Ersoy, A. vd. (2004). “Diabetic ketoacidosis following development of de novo diabetes in renal transplant recipient associated with tacrolimus”. Transplantation Proceedings, 36(5), 1407-1410.0041-1345https://doi.org/10.1016/j.transproceed.2004.04.080https://www.sciencedirect.com/science/article/pii/S0041134504005123http://hdl.handle.net/11452/26288Although drugs used in renal transplant recipients such as steroids, cyclosporine, and particularly, tacrolimus have diabetogenic potential, diabetic ketoacidosis is uncommon. There are few data concerning the long-term follow-up of these patients. Diabetic ketoacidosis occurred in a renal transplant recipient following de novo development associated with tacrolimus.eninfo:eu-repo/semantics/closedAccessImmunologySurgeryTransplantationKidney-transplantationAllograft recipientsPatient survivalRandomized-trialRisk-factorsMellitusImmunosuppressionCyclosporineInsulinFK506AdultDiabetic ketoacidosisDrug therapy, combinationFemaleHumansImmunosuppressive agentsKidney transplantationPeritoneal dialysis, continuous ambulatoryPostoperative complicationsTacrolimusTreatment outcomeArticle0002227130000492-s2.0-31425386041407141036515251345ImmunologySurgeryTransplantationKidney Transplantation; Diabetes Mellitus; Transplant RecipientsAdultArticleCase reportClinical featureDiabetes mellitusDiabetic ketoacidosisDisease courseDrug dose reductionFemaleFollow upHumanImmunosuppressive treatmentKidney graft rejectionKidney transplantationLaboratory testPriority journalTreatment failureTreatment outcomeBicarbonateInfusion fluidInsulinSodium chlorideTacrolimus